The radiopharmaceutical will be developed using Fuzionaire Dx's HetSiFA (heteroaromatic silicon-fluoride acceptors) platform and will be evaluated at McMaster's preclinical nuclear medicine facilities, according to the firm.
Fuzionaire's HetSiFA platform is compatible with fluorine-18 (F-18), which is used for PET imaging.
Copyright © 2022 AuntMinnie.com